Action Davis Select US Equity

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

42,96

Prix Achat

Prix Vente

Volume échangé

80 975

42,72 Fourchette du Jour 43,3507

37,50 Plage de 52 semaines 46,24

Clôture Veille

43,61

Ouverture

43,18

Dernière Transaction

100

42.96

Dernière heure de transaction

Volume moyen (3 m)

50 310

Volume financier

US$ 3 481 583

VWAP

42,9958

DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Ca

WILMINGTON, Mass., Feb. 26 /PRNewswire/ -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its 2009 corporate highlights and year...

DUSA Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

WILMINGTON, Mass., Feb. 2 PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ:DUSA), a specialty pharmaceutical company focused...

DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009

WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and...

DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results

Q3 Domestic PDT revenues up 32% year over year; Q3 Non-GAAP loss improves 86% year over year to ($0.2) million WILMINGTON, Mass., Nov. 6...

DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units

WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused...

DUSA Pharmaceuticals Named to Deloitte's 2009 Technology Fast 500 List of Fastest Growing Companies in North America

Second Consecutive Year DUSA Has Been Recognized WILMINGTON, Mass., Oct. 21 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R...

DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

WILMINGTON, Mass., Sept. 2 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA), a dermatology company that is developing and...

DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results

Q2 Domestic PDT revenues up 24% year over year; Kerastick margins reach a record high of 85% WILMINGTON, Mass., Aug. 11 /PRNewswire-FirstCall/...

DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call

WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq GM: DUSA) announces that its corporate highlights and...

Amex to Trade Options on Nine Securities

Amex to Trade Options on Nine Securities NEW YORK, March 8 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-1.78	-3.9785426911	44.74	45.25	42.77	47700	43.87594399	SP
4	-2.58	-5.66534914361	45.54	46.24	42.77	57072	45.04656047	SP
12	-1.48	-3.3303330333	44.44	46.24	41.77	50310	44.2509331	SP
26	2.57	6.36296112899	40.39	46.24	38.66	37734	43.83541258	SP
52	4.12	10.6076210093	38.84	46.24	37.5	32466	42.13866441	SP
156	11.29	35.6488790654	31.67	46.24	24.67	27331	34.82341447	SP
260	10.24	31.2958435208	32.72	46.24	24.67	25084	34.81571928	SP

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Davis Select US Equity (DUSA)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

DUSA Dernières nouvelles

DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Ca

DUSA Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009

DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results

DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units

DUSA Pharmaceuticals Named to Deloitte's 2009 Technology Fast 500 List of Fastest Growing Companies in North America

DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results

DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call

Amex to Trade Options on Nine Securities

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Davis Select US Equity (DUSA) Cours

Davis Select US Equity (DUSA)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

DUSA Dernières nouvelles

DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Ca

DUSA Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009

DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results

DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units

DUSA Pharmaceuticals Named to Deloitte's 2009 Technology Fast 500 List of Fastest Growing Companies in North America

DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results

DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call

Amex to Trade Options on Nine Securities

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités